• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Role of Kras mutations in intestinal tumor progression

Research Project

Project/Area Number 16K18430
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Tumor biology
Research InstitutionWakayama Medical University (2017)
Japanese Foundation for Cancer Research (2016)

Principal Investigator

Jun Oyanagi  和歌山県立医科大学, 医学部, 特別研究員 (80716069)

Project Period (FY) 2016-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywordsオルガノイド / リキッドバイオプシー / 消化器がん
Outline of Final Research Achievements

We established 42 organiod derived from surgically resected polyps from five familial adenomatous polyposis(FAP) patients. Comprehensive gene expression analysis revealed that some genes are differentially expressed between attenuated FAP(AFAP)-derived organoids and classical FAP(CFAP)-derived organoids. Drug sensitivity assay demonstrated that AFAP-derived KRAS mutant organoid are sensitive to MEK inhibitors although CFAP-derived KRAS mutant organoids are resistant. These data suggest that the differentially expressed genes regulate sensitivity to RAS signal inhibitors.
We explored predictive biomarkers for immune checkpoint inhibitors. Using multiplex assay system, 57 serum proteins were analyzed. We identified proteins associated with clinical benefits from nivolumab. We also identified proteins associated with onset of immune-related adverse events(irAEs). However, no overlapped proteins were identified between clinical benefits and irAE onset.

Report

(3 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • Research Products

    (3 results)

All 2018 2017

All Presentation (3 results) (of which Int'l Joint Research: 2 results)

  • [Presentation] Predictive values of serum protein levels in advanced non-small-cell lung cancer patients treated with nivolumab2018

    • Author(s)
      Jun Oyanagi, Yasuhiro Koh, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
    • Organizer
      American Association for Cancer Research
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] FAP organoids as tools to explore the CRC tumorigenesis2017

    • Author(s)
      Ryoji Yao, Jun Oyanagi, Satoshi Nagayama, Tetsuo Noda
    • Organizer
      日本癌学会
    • Related Report
      2017 Annual Research Report
  • [Presentation] Serial evaluation of multiple serum protein levels in non-small-cell lung cancer patients treated with nivolumab2017

    • Author(s)
      Jun Oyanagi, Yasuhiro Koh, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
    • Organizer
      AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi